A message from the Trump family on gold, retirement accounts,
and what could come next. SMART
STOCK CATCHERS

Daily Briefing

Private Market Window Robotics Repricing Is
Coming. $5.48/Share Ends 9/17 Invest at $5.48/Share
( [link removed] )
8,000X Oversubscription Could
Reset Robotics Stocks Robotics stocks are having a pivotal
moment. And one of those stocks resets its price in days — 9/17
is the cutoff to get in before it does.

A recent robotics IPO was oversubscribed 8,000X, and nuts and
bolts flew in celebration.

Experts say this frenzy is about to reprice robotics stocks
everywhere — including Miso, whose current price disappears on
9/17.

Everyday investors who moved fast didn't miss it. The ones who
waited are the ones asking 'what happened to the price?' a
private-stage company named Miso Robotics
( [link removed] )
.

Miso's Flippy robot works the fry station and was already
boosting profits up to 4x for restaurant brands like White
Castle. That led industry powerhouse Ecolab to invest in Miso’s
growth and NVIDIA to collaborate
( [link removed] )
. Mechanical robot with candlestick chart
( [link removed] )
Now, after Miso made two major asset acquisitions in 2026

( [link removed] )
, Flippy is the star of Miso’s expanding ecosystem. Customers
think of it as the new operating system for modern restaurants.

This year alone, Miso added big-name customers like Jersey
Mike’s and Cinnabon, and grew their patent portfolio by ~10X to
over 300. Their robots have even expanded beyond restaurants,
entering college campuses and NBA arenas
( [link removed] )
.

44,000+ people already claimed their stake — before an
8,000X-oversubscribed IPO put a spotlight on the whole sector.
That spotlight won't make the price wait for you.
( [link removed] )


But hurry. ⏳ Days left. $5.48/share ends September 17 — after
that, you're chasing a repriced market instead of getting ahead
of it.
( [link removed] )
Miso Robotics is offering securities through the use of
an Offering Statement that has been qualified by the Securities
and Exchange Commission under Tier II of Regulation A. A copy of
the Final Offering Circular that forms a part of the Offering
Statement may be obtained from: invest.misorobotics.com/
( [link removed] )
THE EDGE - BRIEF NO. 38 A
2.3-Million-Person Study Traced 24 Chains Where the Fix Was Never
Diagnosed as the Cause A side effect from an existing treatment
kept getting mistaken for a brand-new problem, which then
triggered a second, separate fix, layered on top of the first,
without anyone tracing the second problem back to its actual
origin. WHAT WAS ASSUMED A new symptom showing up after an
existing treatment has already begun is treated as a new,
separate problem requiring its own fix, rather than first being
checked against the treatment already in place as a possible
cause. WHAT GOT TESTED Published in The BMJ, a team led by
Dr. Paula Rochon examined prescription records for 2,297,942
older adults in Ontario, testing 65 previously flagged drug
sequences where treating a side effect as a new condition had
been suspected but not confirmed at population scale. BY THE
NUMBERS 24 of 65 CONFIRMED CHAINS, OUT OF 65 SUSPECTED Of the
65 previously suspected sequences, 24 met every threshold the
team set for being both common and closely linked in time,
confirming that a side effect being mistaken for a new condition
is a common, population-level pattern rather than a rare edge
case. Strongest signal, most consequential fix WHERE THE
MISATTRIBUTION HAD THE HIGHEST STAKES The single strongest chain
in the entire dataset ran from steroids to antipsychotics, an
added medication the study authors describe as carrying important
risks for older adults on its own. Confusion or agitation from
the steroid, showing up weeks later, is what most often triggered
the second prescription rather than a second look at the first.
THE TAKEAWAY The researchers are direct that this describes
patterns across a population, not an error in any single case,
and note that automated review tools and closer coordination
between prescribers could catch a cascade before a second fix
gets layered on. The underlying mechanism is simple to state and
easy to miss in the moment: a new problem appearing after an
existing fix was already in motion gets evaluated as a fresh,
standalone issue, rather than checked first against the fix
already running. Worth applying the same check to any new problem
that shows up after an existing solution was already in place,
whether the two ever get compared side by side, or whether the
new problem simply gets its own separate fix layered on top
without anyone tracing it back. PRIMARY SOURCE
ScienceDaily / The BMJ, Lunenfeld-Tanenbaum Research Institute -
Your next prescription could be treating a side effect from the
last one
( [link removed] )
This brief summarizes published research for general
context and does not constitute financial or medical advice.
Individual results and risk tolerance vary; consult a licensed
professional before acting on any of the topics discussed.
all details here
( [link removed] ) About
This Publication

SmartStockCatchers.com is an independent digital publication
operated by Immersion Technologies LLC.

What to Expect. Each edition brings you curated insights,
practical breakdowns, and forward-looking analysis on technology
and digital innovation — written to inform, not overwhelm. No
fluff, no filler. Just content worth your time.

Views & Opinions. For informational purposes only. Not
investment, financial, or legal advice. Always consult a licensed
professional before making financial decisions. See our Privacy
Policy
( [link removed] )
and Terms & Conditions
( [link removed] )
.

Got a thought, a question, or just want to say hi? Hit reply —
we actually read those and love hearing from our readers.

© 2026 Immersion Technologies LLC. All rights reserved.
260 Chapman Rd, Newark, DE 19702, United States Unsubscribe (
[link removed] )